📊 NMTC Key Takeaways
Is NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) a Good Investment?
NeuroOne shows promising 163.5% YoY revenue growth and 54% gross margins indicating product-market fit, but faces severe profitability and sustainability challenges with operating losses of -72.1% margin and free cash flow burn of -$4.5M annually. At current cash burn rates, the company has less than one year of cash runway without additional capital or dramatic profitability improvement, representing material financial distress risk.
NeuroOne shows strong top-line momentum with 163% YoY revenue growth and healthy 54% gross margins, supported by a clean, low-leverage balance sheet and robust liquidity. However, the business remains unprofitable with materially negative operating cash flow and free cash flow, indicating ongoing cash burn. The outlook hinges on achieving operating leverage and demonstrating a credible path to break-even without dilutive financing.
Why Buy NEUROONE MEDICAL TECHNOLOGIES Corp Stock? NMTC Key Strengths
- Strong revenue growth of 163.5% YoY demonstrates significant market demand
- Healthy 54% gross margin indicates strong product-level unit economics
- Excellent liquidity position with 4.38x current ratio and minimal leverage (0.01x debt/equity)
- Improving EPS trajectory with 80.4% YoY improvement despite remaining unprofitable
- Low debt burden provides flexibility for operations and potential restructuring
- Rapid revenue growth
- Healthy gross margin profile
- Strong liquidity and minimal debt
NMTC Stock Risks: NEUROONE MEDICAL TECHNOLOGIES Corp Investment Risks
- Severe cash burn of $4.5M annually with only $2.8M cash reserves—less than one year of runway without additional capital
- Deep unprofitability across all margins: -72.1% operating margin, -66.7% net margin, -65.6% ROE
- Operating cash flow negative at -$4.4M, indicating core operations consume rather than generate cash
- Early-stage commercialization with very small revenue base ($5.3M) relative to operating expenses
- Company will require capital raise or dramatic operational change to avoid insolvency within 12 months
- Sustained negative free cash flow
- Unproven operating leverage to profitability
- Potential need for external capital/dilution
Key Metrics to Watch
- Operating cash flow trajectory—must turn positive to avoid immediate solvency concerns
- Cash runway depletion rate and timing of next financing event
- Revenue growth acceleration and gross margin sustainability as scale increases
- Operating expense reduction or achievement of operating profitability
- Working capital management and inventory/receivables efficiency
- Operating margin to break-even
- Quarterly operating cash flow
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.38x current ratio provides a solid financial cushion.
NMTC Profit Margin, ROE & Profitability Analysis
NMTC vs Healthcare Sector: How NEUROONE MEDICAL TECHNOLOGIES Corp Compares
How NEUROONE MEDICAL TECHNOLOGIES Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NEUROONE MEDICAL TECHNOLOGIES Corp Stock Overvalued? NMTC Valuation Analysis 2026
Based on fundamental analysis, NEUROONE MEDICAL TECHNOLOGIES Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NEUROONE MEDICAL TECHNOLOGIES Corp Balance Sheet: NMTC Debt, Cash & Liquidity
NMTC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: NEUROONE MEDICAL TECHNOLOGIES Corp's revenue has grown significantly by 5,007% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.46 indicates the company is currently unprofitable.
NMTC Revenue Growth, EPS Growth & YoY Performance
NMTC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $1.4M | -$485.3K | $-0.09 |
| Q1 2026 | $2.9M | -$1.4M | $-0.03 |
| Q3 2025 | $825.8K | -$1.5M | $-0.03 |
| Q2 2025 | $1.4M | -$485.3K | $-0.02 |
| Q1 2025 | $977.6K | $1.8M | $0.06 |
| Q3 2024 | $629.9K | -$1.7M | $-0.10 |
| Q2 2024 | $466.2K | -$1.7M | $-0.11 |
| Q1 2024 | $114.6K | -$1.7M | $-0.11 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NEUROONE MEDICAL TECHNOLOGIES Corp Dividends, Buybacks & Capital Allocation
NMTC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for NEUROONE MEDICAL TECHNOLOGIES Corp (CIK: 0001500198)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NMTC
What is the AI rating for NMTC?
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NMTC's key strengths?
Claude: Strong revenue growth of 163.5% YoY demonstrates significant market demand. Healthy 54% gross margin indicates strong product-level unit economics. ChatGPT: Rapid revenue growth. Healthy gross margin profile.
What are the risks of investing in NMTC?
Claude: Severe cash burn of $4.5M annually with only $2.8M cash reserves—less than one year of runway without additional capital. Deep unprofitability across all margins: -72.1% operating margin, -66.7% net margin, -65.6% ROE. ChatGPT: Sustained negative free cash flow. Unproven operating leverage to profitability.
What is NMTC's revenue and growth?
NEUROONE MEDICAL TECHNOLOGIES Corp reported revenue of $5.3M.
Does NMTC pay dividends?
NEUROONE MEDICAL TECHNOLOGIES Corp does not currently pay dividends.
Where can I find NMTC SEC filings?
Official SEC filings for NEUROONE MEDICAL TECHNOLOGIES Corp (CIK: 0001500198) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NMTC's EPS?
NEUROONE MEDICAL TECHNOLOGIES Corp has a diluted EPS of $-0.44.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NMTC a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, NEUROONE MEDICAL TECHNOLOGIES Corp has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NMTC stock overvalued or undervalued?
Valuation metrics for NMTC: ROE of -65.6% (sector avg: 15%), net margin of -66.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NMTC stock in 2026?
Our dual AI analysis gives NEUROONE MEDICAL TECHNOLOGIES Corp a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NMTC's free cash flow?
NEUROONE MEDICAL TECHNOLOGIES Corp's operating cash flow is $-4.4M, with capital expenditures of $79.3K. FCF margin is -85.6%.
How does NMTC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -66.7% (avg: 12%), ROE -65.6% (avg: 15%), current ratio 4.38 (avg: 2).